<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122684">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885572</url>
  </required_header>
  <id_info>
    <org_study_id>pfm 12k001 TiLOOP Bra</org_study_id>
    <nct_id>NCT01885572</nct_id>
  </id_info>
  <brief_title>National, Multicenter PMS Study &quot;Patient Reported Outcome&quot; in Breast Reconstruction Following Mastectomy With TiLOOP Bra</brief_title>
  <acronym>PRO-BRA</acronym>
  <official_title>National, Multicenter Post-market Surveillance Study &quot;Patient Reported Outcome&quot; in Breast Reconstruction Following Mastectomy With Titaniferously Coated Polypropylene Mesh (TiLOOP Bra)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfm Medical Mepro Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>pfm medical ag</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>pfm medical titanium gmbh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfm Medical Mepro Gmbh</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentre, non-randomised, observational clinical device investigation will be
      performed to obtain postmarketing information on the TiLOOP® Bra and in particular on the
      improvement of the patients' quality of life as well as on the rate of complications of the
      device under investigation.

      The objective of this clinical investigation is to establish the feasibility, efficacy and
      safety of the TiLOOP® Bra.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PRO</measure>
    <time_frame>12 months after breast reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the Patient Reported Outcome (PRO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRO</measure>
    <time_frame>6 and 24 months after breast reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the Patient Reported Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication Rate</measure>
    <time_frame>after 6, 12 and 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complication rate of the first 60 patients in the 6 month follow-up and of all patients after 6, 12 and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Success</measure>
    <time_frame>6, 12 and 24 months after breast reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cosmetic success confirming the reinforcement will be assessed by the patient and an independent professional at a photo. The questions posed are part of the validated Breast Q questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Breast Reconstruction After Mastectomy</condition>
  <arm_group>
    <arm_group_label>TiLOOP Bra</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with TiLOOP Bra</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TiLOOP Bra</intervention_name>
    <description>Titaniferously coated polypropylene mesh</description>
    <arm_group_label>TiLOOP Bra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The TiLOOP®Bra is designed to assist oncologically indexed skin sparing mastectomy or
        subcutaneous mastectomy with preservation of the nipple-areola-complex during primary
        breast reconstruction, secondary breast reconstruction or corrective breast surgery.
        Patients shall be included if they meet all of the following criteria:

        Clinical Criteria (reason):

          -  women with indication of prophylactic operation or oncoplastic operation with support
             of a mesh implant

          -  women with histologically confirmed breast cancer or precancerosis or genetic
             pre-existing conditions with increased risk of breast cancer or with a family history

          -  the health of women must comply with ECOG (Eastern Cooperative Oncology Group)
             performance status 0-2

        Study-related inclusion criteria - Legal reasons:

          -  Patient is mentally able to understand the nature, aims, or possible consequences of
             the clinical investigation

          -  Patient information has been handed out and all written consents are at hand.

          -  Patient is between 18 and 75 years old.

        Exclusion Criteria:

        Patients must be excluded if any of the following conditions exist or cannot be excluded:

        Device-related exclusion criteria (contraindications):

        Pathological or physical condition precluding such as:

          -  Pregnancy or breast-feeding patients

          -  Known intolerance to the mesh-implants under investigation.

        Study-related exclusion criteria - Medical reasons:

          -  metastatic breast cancer

          -  medicamentous regulated diabetes with blood sugar level &gt;250

          -  inadequate bone marrow function with neutrophil granulocytes  &lt;1500 and blood plates
             &lt; 10000/µl

          -  patient with known contraindication to mesh-implants or plastic-reconstructive breast
             operations

        Study-related exclusion criteria - Legal reasons:

          -  Lack of written patients informed consent.

          -  Lack of patient compliance regarding data collection, treatment or follow-up
             investigations in the scope of the protocol.

          -  Patient is institutionalized by court or official order (MPG§20.3).

          -  Participation in another operative clinical investigation.

        It is thought that the study-related exclusion criteria will not significantly influence
        the sample of the population under investigation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Paepke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University Munich, Ismaningerstrasse 22, 81675 Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina Tofall</last_name>
    <email>sabrina.tofall@pfmmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helios Kliniken</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christine Mau, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Kliniken am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andree Faridi, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Gertrauden Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jens-Uwe Blohmer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc Thill, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Krankenhaus</name>
      <address>
        <city>Koeln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anette Meire, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universität</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Paepke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Max Dieterich, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast reconstruction</keyword>
  <keyword>mastectomy</keyword>
  <keyword>mesh</keyword>
  <keyword>breast cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
